Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin

BACKGROUND. Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Chmielecki, Juliann, Ross, Jeffrey S., Wang, Kai, Frampton, Garrett M., Palmer, Gary A., Ali, Siraj M., Palma, Norma, Morosini, Deborah, Miller, Vincent A., Yelensky, Roman, Lipson, Doron, Stephens, Philip J.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2015
Teme:
Cancer Diagnostics and Molecular Pathology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294606/
https://ncbi.nlm.nih.gov/pubmed/25480824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0234
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items